Pelthos Therapeutics Inc. (PTHS)
AMEX AMEX Primary 
Pelthos Therapeutics Q1 Earnings Call Highlights
Pelthos Therapeutics NYSEAMERICAN: PTHS reported higher first-quarter revenue as prescriptions for its lead product, ZELSUVMI, continued to grow in the treatment's third full quarter since launch, executives said on the company's 2026 first-quarter earnings call.
Pelthos Therapeutics Inc. (PTHS) Q1 2026 Earnings Call Transcript
Pelthos Therapeutics Inc. (PTHS) Q1 2026 Earnings Call Transcript
Pelthos Therapeutics Inc. (PTHS) Reports Q1 Loss, Beats Revenue Estimates
Pelthos Therapeutics Inc. (PTHS) came out with a quarterly loss of $3.09 per share versus the Zacks Consensus Estimate of a loss of $4. This compares to a loss of $3.2 per share a year ago.
Pelthos Therapeutics Inc. (PTHS) Q4 2025 Earnings Call Transcript
Pelthos Therapeutics Inc. (PTHS) Q4 2025 Earnings Call Transcript
Pelthos Therapeutics Inc. (PTHS) Reports Q4 Loss, Tops Revenue Estimates
Pelthos Therapeutics Inc. (PTHS) came out with a quarterly loss of $2.83 per share versus the Zacks Consensus Estimate of a loss of $3.95. This compares to a loss of $3.2 per share a year ago.
Pelthos Pharmaceuticals: Off To A Strong Start With Zelsuvmi, Continued Sales Growth Is Likely
Pelthos Pharmaceuticals has launched Zelsuvmi, the first at-home FDA-approved treatment for molluscum contagiosum, showing strong initial sales growth. PTHS reported $7.1 million net revenue in its first commercialization quarter, prompting an expansion of its sales force. The company targets breakeven by end-2026, with peak revenue projections of $175 million likely conservative given rapid prescription uptake and market size.
